Bicycle therapeutics reports recent business progress and third quarter 2023 financial results and announces upcoming r&d day

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the third quarter ended september 30, 2023, and provided recent corporate updates. “in the third quarter, we took important steps toward achieving our goal of quickly getting our novel therapies to those who need them. we are ex.
BCYC Ratings Summary
BCYC Quant Ranking